Where it trades today
trading 33% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ALGN trades at 25.6x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 29.1%, above the sector norm of 22.0%, so position sizing matters more than usual.
- ALGN remains in a bearish short-term trend and sits 26.4% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- ALGN is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in ALGN.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ALGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ALGN. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Align Technology does
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus;…
Employees
20,435
Industry
Medical Instruments & Supplies
Headquarters
Tempe, United States
What analysts expect
ALGN carries a buy consensus from 15 analysts, with an average price target of $208.60 versus $147.61 today (+41.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ALGN generated $4.14B in trailing revenue (4.3% year over year), with a 10.0% net margin, and $594.11M of free cash flow, supported by $981.75M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.03B | $2.71B | $585.31M | $410.35M | $5.66 | $490.78M |
| 2024 | $4.00B | $2.80B | $671.76M | $421.36M | $5.63 | $622.65M |
| 2023 | $3.86B | $2.71B | $656.65M | $445.05M | $5.82 | $608.06M |
| 2022 | $3.73B | $2.63B | $654.05M | $361.57M | $4.62 | $276.83M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ALGN beside the healthcare names it is usually measured against.
What the chart is saying
Align Technology trades at $147.61, 26.4% below its 52-week high. With a beta of 1.64, it shows more sensitivity to what the wider market does.
Questions people ask about it
Is ALGN a good buy right now?
Align Technology trades at 25.6x earnings. This is near market average. Current risk level is Medium based on 29.1% volatility.
Does ALGN pay dividends?
Align Technology does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is ALGN?
With 30-day annualized volatility of 29.1% and beta of 1.64, ALGN is classified as Medium risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for ALGN?
The average analyst price target for Align Technology (ALGN) is $208.60 based on 15 analyst estimates, about 41.3% above the current price of $147.61. The published range runs from $170.00 to $240.00.
How much revenue does ALGN generate?
Align Technology reported $4.14B in trailing twelve-month revenue. Revenue growth is running at 4.3% year over year. Net margin sits at 10.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.